Matinas BioPharma Holdings, Inc. (MTNB)

MTNB Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	1.1	3.19	0.03	0.16
Revenue Growth (YoY)	-	-65.62%	9560.61%	-79.16%	76.29%
Cost of Revenue	11.43	14.49	16.68	14.58	14.36
Gross Profit	-11.43	-13.39	-13.49	-14.55	-14.2
Selling, General & Admin	8.73	10.37	11.1	10.19	10.01
Operating Expenses	8.73	10.37	11.1	10.19	10.01
Operating Income	-20.16	-23.77	-24.59	-24.74	-24.21
Interest Expense	-0	-0	-0	-0	-0.01
Other Non Operating Income (Expenses)	0.26	0.83	3.59	1.46	1.76
EBT Excluding Unusual Items	-19.9	-22.94	-21	-23.28	-22.46
Impairment of Goodwill	-2.09	-	-	-	-
Gain (Loss) on Sale of Investments	-	-	-	-	0.01
Asset Writedown	-2.34	-	-	-	-
Pretax Income	-24.33	-22.94	-21	-23.28	-22.45
Income Tax Expense	-0.08	-	-	-	-
Net Income	-24.25	-22.94	-21	-23.28	-22.45
Preferred Dividends & Other Adjustments	-	-	-	0.4	0.79
Net Income to Common	-24.25	-22.94	-21	-23.68	-23.24
Shares Outstanding (Basic)	5	4	4	4	4
Shares Outstanding (Diluted)	5	4	4	4	4
Shares Change (YoY)	11.98%	0.21%	3.16%	6.75%	35.61%
EPS (Basic)	-4.98	-5.28	-4.84	-5.63	-5.90
EPS (Diluted)	-4.98	-5.28	-4.84	-5.63	-5.90
Free Cash Flow	-15.89	-15.5	-20.05	-15.48	-17.37
Free Cash Flow Per Share	-3.27	-3.57	-4.62	-3.68	-4.41
Operating Margin	-	-2168.43%	-771.33%	-74954.54%	-15288.38%
Profit Margin	-	-2093.25%	-658.63%	-71754.54%	-14678.10%
Free Cash Flow Margin	-	-1413.87%	-628.86%	-46918.18%	-10972.81%
EBITDA	-19.79	-23.37	-24.23	-24.46	-23.92
D&A For EBITDA	0.37	0.39	0.36	0.28	0.29
EBIT	-20.16	-23.77	-24.59	-24.74	-24.21

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q